ORCID as entered in ROS

Select Publications
2024, 'Reply to: “ ‘One-stop-shop’ point-of-care hepatitis C RNA testing intervention in the prison – some issues”', Journal of Hepatology, 80, pp. e107 - e108, http://dx.doi.org/10.1016/j.jhep.2023.10.020
,2024, 'Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study', Value in Health, 27, pp. 216 - 225, http://dx.doi.org/10.1016/j.jval.2023.10.013
,2024, 'Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination', Open Forum Infectious Diseases, 11, pp. ofad637, http://dx.doi.org/10.1093/ofid/ofad637
,2024, 'Incidence of hepatitis C virus infection in the prison setting: The SToP-C study', Journal of Viral Hepatitis, 31, pp. 21 - 34, http://dx.doi.org/10.1111/jvh.13895
,2024, 'The time of cure: hepatitis C treatment and the matter of reinfection among people who inject drugs', Health Sociology Review, 33, pp. 104 - 118, http://dx.doi.org/10.1080/14461242.2024.2315031
,2024, 'We have reached single-visit testing, diagnosis, and treatment for hepatitis C infection, now what?', Expert Review of Molecular Diagnostics, 24, pp. 177 - 191, http://dx.doi.org/10.1080/14737159.2023.2292645
,2023, 'Deimplementation in the provision of opioid agonist treatment to achieve equity of care for people engaged in treatment: a qualitative study', Implementation Science, 18, http://dx.doi.org/10.1186/s13012-023-01281-4
,2023, 'Effect of incarceration and opioid agonist treatment transitions on risk of hospitalisation with injection drug use-associated bacterial infections: A self-controlled case series in New South Wales, Australia', International Journal of Drug Policy, 122, http://dx.doi.org/10.1016/j.drugpo.2023.104218
,2023, 'Global, regional, and country-level coverage of testing and treatment for HIV and hepatitis C infection among people who inject drugs: a systematic review', Lancet Global Health, 11, pp. e1885 - e1898, http://dx.doi.org/10.1016/S2214-109X(23)00461-8
,2023, 'Evaluating the prevalence of current hepatitis C infection and treatment among Aboriginal and Torres Strait Islander peoples who inject drugs in Australia: The ETHOS engage study', Drug and Alcohol Review, 42, pp. 1617 - 1632, http://dx.doi.org/10.1111/dar.13723
,2023, 'Health-related quality of life among people who inject drugs in Australia', Quality of Life Research, 32, pp. 3195 - 3207, http://dx.doi.org/10.1007/s11136-023-03465-3
,2023, 'Hepatitis C Treatment Uptake Following Dried Blood Spot Testing for Hepatitis C RNA in New South Wales, Australia: The NSW DBS Pilot Study', Open Forum Infectious Diseases, 10, http://dx.doi.org/10.1093/ofid/ofad517
,2023, 'Joint statement in support of hepatitis C human challenge studies', Lancet Gastroenterology and Hepatology, 8, pp. 967 - 969, http://dx.doi.org/10.1016/S2468-1253(23)00314-X
,2023, 'Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study', Jhep Reports, 5, http://dx.doi.org/10.1016/j.jhepr.2023.100867
,2023, 'Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study', Lancet Gastroenterology and Hepatology, 8, pp. 879 - 907, http://dx.doi.org/10.1016/S2468-1253(23)00197-8
,2023, 'Reinfection incidence and risk among people treated for recent hepatitis C virus infection', AIDS, 37, pp. 1883 - 1890, http://dx.doi.org/10.1097/QAD.0000000000003651
,2023, 'A ‘one-stop-shop’ point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study', Journal of Hepatology, 79, pp. 635 - 644, http://dx.doi.org/10.1016/j.jhep.2023.04.019
,2023, 'Agreement between self-reported illicit drug use and biological samples: a systematic review and meta-analysis', Addiction, 118, pp. 1624 - 1648, http://dx.doi.org/10.1111/add.16200
,2023, 'Typology of laws restricting access to methadone treatment in the United States: A latent class analysis', International Journal of Drug Policy, 119, http://dx.doi.org/10.1016/j.drugpo.2023.104141
,2023, 'Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis', Lancet Microbe, 4, pp. e622 - e631, http://dx.doi.org/10.1016/S2666-5247(23)00108-8
,2023, 'Optimizing point-of-care testing strategies for diagnosis and treatment of hepatitis C virus infection in Australia: a model-based cost-effectiveness analysis', Lancet Regional Health Western Pacific, 36, pp. 100750, http://dx.doi.org/10.1016/j.lanwpc.2023.100750
,2023, 'Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive study', Canadian Liver Journal, 6, pp. 190 - 200, http://dx.doi.org/10.3138/canlivj-2022-0040
,2023, 'Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs', Value in Health, 26, pp. 883 - 892, http://dx.doi.org/10.1016/j.jval.2022.12.016
,2023, 'Reducing barriers to the hepatitis C care cascade in prison via point-of-care RNA testing: a qualitative exploration of men in prison using an integrated framework', Addiction, 118, pp. 1153 - 1160, http://dx.doi.org/10.1111/add.16137
,2023, '‘I just thought that was the best thing for me to do at this point’: Exploring patient experiences with depot buprenorphine and their motivations to discontinue', International Journal of Drug Policy, 115, http://dx.doi.org/10.1016/j.drugpo.2023.104002
,2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', Lancet Global Health, 11, pp. e659 - e672, http://dx.doi.org/10.1016/S2214-109X(23)00057-8
,2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', Lancet Global Health, 11, pp. e673 - e683, http://dx.doi.org/10.1016/S2214-109X(23)00058-X
,2023, '“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103998
,2023, 'Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103982
,2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7
,2023, 'Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis', Drug and Alcohol Review, 42, pp. 569 - 581, http://dx.doi.org/10.1111/dar.13595
,2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791
,2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469
,2023, 'Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar', Viruses, 15, pp. 521, http://dx.doi.org/10.3390/v15020521
,2023, 'Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection', Journal of Addictive Diseases, 41, pp. 213 - 224, http://dx.doi.org/10.1080/10550887.2022.2088978
,2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761
,2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917
,2023, 'People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study', Drug and Alcohol Review, 42, pp. 203 - 212, http://dx.doi.org/10.1111/dar.13531
,2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011
,2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009
,2023, 'Decentralised point-of-care testing for acute, chronic and infectious disease – benefits and challenges', Pathology, 55, pp. S7 - S7, http://dx.doi.org/10.1016/j.pathol.2022.12.029
,2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876
,2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
,2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463
,2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049
,2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, 175, pp. 1221 - 1229, http://dx.doi.org/10.7326/M21-4119
,2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746
,2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
,2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
,2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496
,